These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3488924)

  • 1. Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.
    Bubeník J; Kieler J; Indrová M
    Folia Biol (Praha); 1986; 32(3):209-11. PubMed ID: 3488924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
    Símová J; Bubeník J; Voitenok NN; Gren E
    Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
    Bubeník J; Indrová M; Toulcová A
    Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour efficacy of IL-1 and IL-2.
    Bubeník J; Indrová M; Holán V
    Folia Biol (Praha); 1988; 34(1):42-7. PubMed ID: 3260564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
    Indrová M; Bubeník J; Toulcová A
    Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active suppression of the proliferative response to interleukin-2 in tumour-bearing mice.
    Zajícová A; Holán V
    Folia Biol (Praha); 1990; 36(6):301-11. PubMed ID: 2279584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.
    Bubeník J; Perlmann P; Indrová M; Símová J; Jandlová T; Neuwirt J
    Cancer Immunol Immunother; 1983; 14(3):205-6. PubMed ID: 6601512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
    Silagi S; Schaefer AE
    J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of a carcinogen-induced murine sarcoma with soluble tumor-specific transplantation antigens.
    Kahan BD; Tanaka T; Pellis NR
    J Natl Cancer Inst; 1980 Nov; 65(5):1001-4. PubMed ID: 6159495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
    Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
    Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of repeated cycles of local IL-2 injections in mice carrying slowly growing tumour grafts.
    Símová J; Bubeník J; Indrová M; Bubeníková D; Jandlová T
    Folia Biol (Praha); 1993; 39(6):315-22. PubMed ID: 7926162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines.
    Kono K; Petersson M; Ciupitu AM; Wen T; Klein G; Kiessling R
    Cancer Res; 1995 Dec; 55(23):5648-55. PubMed ID: 7585649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of newly induced murine sarcomas.
    Shu SY; Rosenberg SA
    Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
    Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.